Research Analysts Set Expectations for TScan Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:TCRX)

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Wedbush dropped their Q1 2024 earnings per share (EPS) estimates for TScan Therapeutics in a note issued to investors on Wednesday, April 17th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($0.27) for the quarter, down from their previous forecast of ($0.26). Wedbush has a “Outperform” rating and a $10.00 price objective on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.04) per share. Wedbush also issued estimates for TScan Therapeutics’ Q2 2024 earnings at ($0.23) EPS, Q3 2024 earnings at ($0.24) EPS, Q4 2024 earnings at ($0.25) EPS, FY2024 earnings at ($0.98) EPS, FY2025 earnings at ($1.08) EPS, FY2026 earnings at ($1.13) EPS and FY2027 earnings at ($0.91) EPS.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Wednesday, March 6th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.08. TScan Therapeutics had a negative return on equity of 60.65% and a negative net margin of 423.86%. The company had revenue of $7.21 million for the quarter, compared to the consensus estimate of $2.94 million.

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of TScan Therapeutics in a research note on Thursday, March 7th.

TScan Therapeutics Trading Down 1.4 %

Shares of TScan Therapeutics stock opened at $6.82 on Friday. The company’s fifty day simple moving average is $7.06 and its 200-day simple moving average is $5.67. The company has a market cap of $326.54 million, a price-to-earnings ratio of -3.61 and a beta of 0.90. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.18. TScan Therapeutics has a 1 year low of $1.62 and a 1 year high of $9.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Pale Fire Capital SE bought a new position in TScan Therapeutics in the third quarter worth $42,000. Letko Brosseau & Associates Inc. bought a new position in shares of TScan Therapeutics during the 3rd quarter valued at about $83,000. Virtu Financial LLC bought a new position in shares of TScan Therapeutics during the 4th quarter valued at about $107,000. State Street Corp lifted its stake in TScan Therapeutics by 60.4% in the 2nd quarter. State Street Corp now owns 38,500 shares of the company’s stock valued at $96,000 after acquiring an additional 14,500 shares in the last quarter. Finally, LPL Financial LLC bought a new stake in TScan Therapeutics in the 2nd quarter valued at approximately $50,000. 82.83% of the stock is owned by institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.